Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
STX-721/PFL-721 (Escalated)
STX-721/PFL-721 (3 dose levels)
+1 more
Locations
24
United States
City of Hope
Duarte, California, United States
City of Hope
Huntington Beach, California, United States
City of Hope
Irvine, California, United States
Levine Cancer Institute - Charlotte
Charlotte, North Carolina, United States
Thomas Jefferson University Research Facility
Philadelphia, Pennsylvania, United States
SCRI Oncology Partners - PPDS
Nashville, Tennessee, United States
Start Date
September 26, 2023
Primary Completion Date
December 1, 2029
Completion Date
December 1, 2029
Last Updated
April 24, 2026
NCT07363252
NCT07144280
NCT07431827
NCT06758401
NCT06427941
NCT06476808
Adele De MASSON, clinical devlopment director, MD, PhD
CONTACT
33 772344916PFL721_medical.team@pierre-fabre.comLead Sponsor
Pierre Fabre Medicament
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions